ClinicalTrials.gg
Biological

Saponin QA-21V1 clinical trials

Also written QS21.

studies test it
26
open now
1
in phase 3
1
first study started
1996

How each study uses saponin QA-21V1 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the saponin QA-21V1 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

QS21
19

Other names

Purified Quillaja Saponin
1
QS-21 Adjuvant
1
QUILLAJA SAPONIN (QS-21)
1

In one entry with another drug

Given together, or one or the other

ACC-001 + QS-21
2

Studies by the year they started

22 studies that test it; most in 1998 (4)

Studies that test saponin QA-21V1, by start year
YearStudies
19961
19984
19992
20003
20011
20021
20073
20092
20121
20191
20211
20221
20261

By phase

A phase 1/2 study counts in both.

Phase 1
14
Phase 2
9
Phase 3
1
No phase
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 6 · Other 20

Memorial Sloan Kettering Cancer Center (10) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Pfizer (4) · Agenus Inc. (2) · University of Kansas Medical Center (1) · U.S. Army Medical Research and Development Command (1) · University of Virginia (1) · Fox Chase Cancer Center (1)

Often tested with

Tested in the same studies.

Vanutide cridificar (4) · HIV Envelope Protein gp120 (2) · GM2-KLH Vaccine (2) · Apricoxib (1) · Neoantigen-HSP70 Peptide Cancer Vaccine AGEN2017 (1) · Incomplete Freund's adjuvant (1) · MUC1-KLH Conjugate Vaccine (1) · MUC1-KLH Vaccine/QS21 (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test saponin QA-21V1.

Studies

Open first, then newest update. How each study uses saponin QA-21V1 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 26

See all 26 studies that test saponin QA-21V1 →

Given beside what is tested · 6 — saponin QA-21V1 is usual care or a partner of the new treatment

Codes

What other systems call saponin QA-21V1 · ClinicalTrials.gg INT003688

  • MeSH (NLM) C078785saponin QA-21V1One source NLM
  • UNII (FDA) 61H83WZX3UQUILLAJA SAPONIN (QS-21)Confirmed FDA, NLM
  • RxNorm 2002417One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.